13F Pro Quality Score

28.9/100

Rank #2,542 of 2,962 stocks

View Materials peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

77.3/100

Profitability

12.7/100

Balance Sheet

9.7/100

Earnings Quality

13.5/100

Free Cash Flow

14.5/100

Institutional Flow

3.5/100

Revenue Scale

12.7/100

Dilution Risk

12.8/100
Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

CDXS Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for CODEXIS, INC. (CDXS), a Materials sector company. 13F Pro's AI-powered ranking engine scores CDXS at 28.9/100 on a 32-signal composite quality model, placing it at rank #2,542 of 2,962 stocks — the bottom half of the AI-ranked universe. CDXS scores in the top quartile across revenue growth (77.3). Areas of concern include institutional flow (3.5) and balance sheet strength (9.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 12.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), CODEXIS, INC. reports quarterly revenue of $14.9M, net income of $-12.0M, free cash flow of $-10.5M. Top institutional holders of CDXS by reported 13-F value include BlackRock, Opaleye Management, abrdn plc, based on the most recent SEC filings. CDXS trades on the Nasdaq exchange and files with the SEC under CIK 1200375. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CDXS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CODEXIS, INC. directly from SEC EDGAR. CODEXIS, INC.'s 13F Pro composite quality score has ranged between 7 and 41 since 2021, currently 28.9 — a stable long-term trajectory across 68 quarterly and live scoring snapshots.

Fun facts about CODEXIS, INC.

Quirks, history, and lore behind CDXS — the kind of stuff that makes a stock memorable.

  • 1
    The Basics
    U.S. biotechnology / specialty chemicals company · listed on Nasdaq · headquartered in California · small-cap.
  • 2
    The Numbers
    Annual revenues in the range of tens of millions of dollars — this is a science-first business, not a blockbuster retailer, with R&D spending that routinely rivals its top line.
  • 3
    The History
    Spun out of Shell's biofuels research in the early 2000s, it pivoted away from fuel and toward the far more lucrative world of engineered enzymes for pharmaceuticals.
  • 4
    The Secret
    Its real product isn't a drug or a chemical — it's a protein engineering platform that redesigns enzymes to do chemistry that nature never figured out, faster and greener.
  • 5
    The Lore
    Its CodeEvolver platform helped Merck's chemistry team build a key step in the synthesis of Januvia (sitagliptin) — a landmark moment that put enzymatic synthesis on the pharma map.
  • 6
    The Giveaway
    The name is basically a portmanteau of "codex" and "esis" — fitting for a company that literally rewrites the genetic code of enzymes for a living. Ticker: four letters, starts with C.
▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$14.9M

Net Income

Q2 2026

$-12.0M

Free Cash Flow

Q2 2026

$-10.5M

ROIC

Q2 2026

-55.5%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+18.6% YoY
$70.4MFY 2025
FY22 $138.6MFY23 $70.1MFY24 $59.3MFY25 $70.4M

Net Income

+32.6% YoY
$-44.0MFY 2025
FY22 $-33.6MFY23 $-76.2MFY24 $-65.3MFY25 $-44.0M

Operating Income

+28.7% YoY
$-41.7MFY 2025
FY22 $-34.9MFY23 $-68.1MFY24 $-58.5MFY25 $-41.7M

EPS (Diluted)

+43.8% YoY
$-0.50FY 2025
FY22 $-0.51FY23 $-1.12FY24 $-0.89FY25 $-0.50

Total Assets

-0.8% YoY
$147.8MFY 2025
FY22 $250.4MFY23 $136.6MFY24 $149.0MFY25 $147.8M

Total Debt

+38.7% YoY
$40.1MFY 2025
FY22 FY23 $0.00FY24 $28.9MFY25 $40.1M

Op. Cash Flow

+60.8% YoY
$-19.4MFY 2025
FY22 $11.3MFY23 $-52.6MFY24 $-49.4MFY25 $-19.4M

Free Cash Flow

+55.6% YoY
$-23.8MFY 2025
FY22 $3.0MFY23 $-57.1MFY24 $-53.7MFY25 $-23.8M

Get alerted when CDXS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for CODEXIS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Top Institutional Holders of CDXS

Companies Similar to CDXS

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

GEVO

Gevo, Inc.

33
AI score
Similar quality profile · 2 shared holders
IAUX

i-80 Gold Corp.

29
AI score
Similar quality profile · 1 shared holders
BDSX

BIODESIX INC

32
AI score
Similar quality profile · 4 shared holders
ARQ

Arq, Inc.

27
AI score
Similar quality profile · 2 shared holders
ADCT

ADC Therapeutics SA

19
AI score
Similar quality profile · 4 shared holders
MP

MP Materials Corp. / DE

33
AI score
Similar quality profile · 1 shared holders
ASPI

ASP Isotopes Inc.

28
AI score
Similar quality profile · 1 shared holders
TELA

TELA Bio, Inc.

23
AI score
Similar quality profile · 3 shared holders

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

Put CDXS on your watchlist

Track score changes the day CODEXIS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is CDXS a good stock to buy?

13F Pro's AI-powered analysis of CODEXIS, INC. (CDXS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Materials sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CDXS are available on the CDXS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CDXS is classified as a small company.

Which hedge funds own CDXS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CDXS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CODEXIS, INC.'s investment landscape.